Medytox Wins Colombia Approval For Atiere Fillers

Medytox has secured product approval for its hyaluronic acid filler 'Atiere' in Colombia, marking a significant expansion of its global reach in the Latin American aesthetic market. The hyaluronic acid filler was granted approval by the National Food and Drug Surveillance Institute (INVIMA) of Colombia on May 2. This achievement, Medytox's second in the Latin American market following the Dominican Republic, positions Colombia as a vital country in the region's aesthetic industry.

In fact, Colombia relies heavily on imports for about 89% of its medical device demand, making it an ideal destination for global companies. With this approval, Medytox has completed a portfolio that covers its hyaluronic acid fillers 'Neuramis' and 'Atiere', as well as its botulinum toxin preparation 'Meditoxin', allowing it to supply all these products in the local market.

This strategic move is expected to enhance Medytox's competitiveness in the local market, enabling it to cater to various procedure demands. Medytox's simultaneous possession of botulinum toxin and filler product lines now allows for a diverse range of options for local medical staff and consumers. Looking ahead, the company plans to sequentially target other Latin American countries, leveraging Colombia as its base to expand its global influence across the entire Latin American region.